Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Diagnosis & Therapy
Published in: Molecular Diagnosis & Therapy 4/2014

Open Access 01-08-2014 | Original Research Article

CYP1A1 Ile462Val Polymorphism as a Risk Factor in Cervical Cancer Development in the Polish Population

Authors: Andrzej Roszak, Margarita Lianeri, Anna Sowińska, Pawel P. Jagodziński

Published in: Molecular Diagnosis & Therapy | Issue 4/2014

Login to get access

Abstract

Background and objective

There are inconsistent data of the cytochrome P450 1A1 (CYP1A1) Ile462Val (rs1048943) single nuclear polymorphism (SNP) as a genetic susceptibility factor for cervical cancer in various populations. Moreover, little is known about the interaction of this SNP with other risk factors, including contraceptive use, postmenopausal status, parity, and tobacco smoking.

Methods

Polymerase chain reaction-restriction fragment length polymorphism was used to study the prevalence of the CYP1A1 Ile462Val SNP in women with cervical cancer (n = 456) and controls (n = 495).

Results

Logistic regression analysis adjusting for age, parity, oral contraceptive use, tobacco smoking, and menopausal status demonstrated that that the CYP1A1 Ile/Val polymorphism was not associated with an increased risk of cervical cancer in all patients. The adjusted odds ratio (OR) for patients with the Ile/Val genotype vs. Ile/Ile genotype was 1.539 (95 % confidence interval [CI] 0.932–2.541, p = 0.091). However, an increase in cervical cancer risk was seen among patients with a positive history of tobacco smoking and parity. The adjusted OR for positive history of tobacco smoking with the Ile/Val vs. Ile/Ile genotypes was 2.978 (95 % CI 1.382–6.418, p = 0.0052). The adjusted OR for parity with the Ile/Val vs. Ile/Ile genotype was 1.739 (95 % CI 1.006–3.009, p = 0.0472).

Conclusion

Our genetic study suggests that the CYP1A1 Ile462Val SNP may be a risk factor for cervical cancer among patients with a positive history of tobacco smoking and parity.
Literature
1.
Jemal A, Center MM, DeSantis C, et al. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893–907.CrossRefPubMed
2.
Georgieva S, Iordanov V, Sergieva S. Nature of cervical cancer and other HPV-associated cancers. J BUON. 2009;14(3):391–8.PubMed
3.
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.CrossRefPubMed
4.
Sasagawa T, Takagi H, Makinoda S. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother. 2012;18(6):807–15.CrossRefPubMed
5.
Castellsague X, Munoz N. Chapter 3: cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;31:20–8.CrossRefPubMed
6.
Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in health and disease. Philos Trans R Soc Lond B Biol Sci. 2013;368(1612):20120431.CrossRefPubMed
7.
McManus ME, Burgess WM, Veronese ME, et al. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochrome P-450. Cancer Res. 1990;50:3367–76.PubMed
8.
Monostory K, Dvorak Z. Steroid regulation of drug-metabolizing cytochromes P450. Curr Drug Metab. 2011;12(2):154–72.CrossRefPubMed
9.
Petersen DD, McKinney CE, Ikeya K, et al. Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet. 1991;48(4):720–5.PubMedCentralPubMed
10.
Gutman G, Morad T, Peleg B, et al. Cyp1a1 and cyp2d6 gene polymorphisms in Israeli Jewish women. Int J Gynecol Cancer. 2009;19(8):1300–2.CrossRefPubMed
11.
Taskiran C, Aktas D, Yigit-Celik N, et al. CYP1A1 gene polymorphism as a risk factor for cervical intraepithelial neoplasia and invasive cervical cancer. Gynecol Oncol. 2006;101(3):503–6.CrossRefPubMed
12.
Joseph T, Chacko P, Wesley R, et al. Germline genetic polymorphisms of cyp1a1, gstm1 and gstt1 genes in Indian cervical cancer: associations with tumor progression, age and human papillomavirus infection. Gynecol Oncol. 2006;101(3):411–7.CrossRefPubMed
13.
Sugawara T, Nomura E, Sagawa T, et al. Cyp1a1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer. 2003;13(6):785–90.CrossRefPubMed
14.
Liu L, Wu G, Xue F, et al. Functional CYP1A1 genetic variants, alone and in combination with smoking, contribute to development of head and neck cancers. Eur J Cancer. 2013.
15.
Han G, Ma Y, Liu P, et al. Quantitative synthesis of the association between the cytochrome P450 1A1 Ile462Val polymorphism and prostate cancer risk. Tumour Biol. 2013;34(3):1511–6.CrossRefPubMed
16.
Ji YN, Wang Q, Suo LJ. CYP1A1 Ile462Val polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: a meta-analysis. PLoS ONE. 2012;7(8):e43397.PubMedCentralCrossRefPubMed
17.
Sergentanis TN, Economopoulos KP, Choussein S, et al. Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and ovarian cancer risk: a meta-analysis. Mol Biol Rep. 2012;39(11):9921–30.CrossRefPubMed
18.
Zhuo X, Zhao H, Chang A, et al. Cytochrome P450 1A1 Ile462Val polymorphism and oral carcinoma risk: an updated meta-analysis including 1,515 cases and 2,233 controls. Tumour Biol. 2012;33(6):2079–89.CrossRefPubMed
19.
Öztürk T, Kahraman ÖT, Toptaş B, et al. The effect of CYP1A1 and GSTM1 gene polymorphisms in bladder cancer development in a Turkish population. In Vivo. 2011;25(4):663–8.PubMed
20.
Jin JQ, Hu YY, Niu YM, et al. CYP1A1 Ile462Val polymorphism contributes to colorectal cancer risk: a meta-analysis. World J Gastroenterol. 2011;17(2):260–6.CrossRefPubMed
21.
Zhuo W, Zhang L, Zhu B, et al. Association between CYP1A1 Ile462Val variation and acute leukemia risk: meta-analyses including 2164 cases and 4160 controls. PLoS ONE. 2012;7(10):e46974.PubMedCentralCrossRefPubMed
22.
Ding FY, Ma GF, Song XH, Shi WH, Lan JY, Yu HY. Relationship between cyp1a1 gene polymorphism and genetic susceptibility of cervical carcinoma. Jiangsu Med J. 2011;37:2562.
23.
Geng J, Shi YR, Wang H, Qin R. Research of cytochrome p450 i a1 lle/val polymorphism and genetic susceptibility in cervical cancer. J Bengbu Med Coll. 2010;35:762.
24.
Shi YR, Geng J, Cheng LQ, Wang H, Zhang Y. Association of cytochrome p450 1a1 gene polymorphisms with cervical cancer. Fudan Univ J Med Sci. 2011;38(05):428–31.
25.
Zhang SH, Kong AR. Polymorphisms of cyp1a1 gene and hpv infection of cervical squamous carcinoma: Master’s thesis of Taishan Medical University; 2009.
26.
Zhang X. P450 1a1 gene polymorphism and cervical cancer level correlation. Jilin Med J. 2011;32:419.
27.
Huang YK, Hsieh HC, Sun JA, et al. Genetic polymorphisms of phase I and phase II xenobiotic enzymes in human papillomavirus related lesion and cancer of the uterine cervix. Tzu Chi Med J. 2006;18(4):267–74.
28.
Yang S, Jia C, Zhu H, et al. CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis. Tumour Biol. 2012;33(6):2265–72.CrossRefPubMed
29.
Sergentanis TN, Economopoulos KP, Choussein S, et al. Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and cervical cancer risk: a meta-analysis. Mol Biol Rep. 2012;39(6):6647–54.CrossRefPubMed
30.
Thun MJ, Henley SJ, Calle EE. Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene. 2002;21(48):7307–25.CrossRefPubMed
31.
Landi MT, Bertazzi PA, Shields PG, et al. Association between CYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics. 1994;4(5):242–6.CrossRefPubMed
32.
Mooney LA, Bell DA, Santella RM, et al. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis (Lond.). 1997;18:503–9.CrossRef
33.
Zhang ZY, Fasco MJ, Huang L, et al. Characterization of purified human recombinant cytochrome P4501A1-lle462 and Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res. 1996;56:3926–33.PubMed
34.
Persson I, Johansson I, Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem Biophys Res Commun. 1997;231:227–30.CrossRefPubMed
35.
Muñoz N, Franceschi S, Bosetti C, et al. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Multicentric Cervical Cancer Study Group. Lancet. 2002;359(9312):1093–101.CrossRefPubMed
Metadata
Title
CYP1A1 Ile462Val Polymorphism as a Risk Factor in Cervical Cancer Development in the Polish Population
Authors
Andrzej Roszak
Margarita Lianeri
Anna Sowińska
Pawel P. Jagodziński
Publication date
01-08-2014
Publisher
Springer International Publishing
Published in
Molecular Diagnosis & Therapy / Issue 4/2014
Print ISSN: 1177-1062
Electronic ISSN: 1179-2000
DOI
https://doi.org/10.1007/s40291-014-0095-2

Other articles of this Issue 4/2014

Molecular Diagnosis & Therapy 4/2014 Go to the issue

Original Research Article

Highly Sensitive KRAS Mutation Detection from Formalin-Fixed Paraffin-Embedded Biopsies and Circulating Tumour Cells Using Wild-Type Blocking Polymerase Chain Reaction and Sanger Sequencing

Review Article

The Economic Considerations and Implications of the Stratification of Future Oncology Therapeutics

Original Research Article

Influence of SREBP-2 and SCAP Gene Polymorphisms on Lipid-Lowering Response to Atorvastatin in a Cohort of Chilean Subjects with Amerindian Background

Original Research Article

Interleukin-18 −607C/A Gene Polymorphism in Egyptian Asthmatic Children

Original Research Article

PAX2 Polymorphisms and Congenital Abnormalities of the Kidney and Urinary Tract in a Brazilian Pediatric Population: Evidence for a Role in Vesicoureteral Reflux

Original Research Article

Tumor Cellularity as a Quality Assurance Measure for Accurate Clinical Detection of BRAF Mutations in Melanoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits